SIAH2 and cancer: SIAH3 appears to be an attractive target for further investigation as its active homologs, SIAH1 and SIAH2, are known to be downstream effectors of the KRAS pathway [63] and have been shown to be associated with cancer progression and poor prognosis in multiple cancers [27,64,65,66,67,68].